HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target.
March 18, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spero Therapeutics maintains a Buy rating and a $7 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Spero Therapeutics. This endorsement reaffirms the firm's confidence in SPRO's potential, likely encouraging both current and potential investors about the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100